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Background: Poor maternal vitamin D intake is a risk factor for subsequent childhood asthma, suggesting that in
utero changes related to vitamin D responsive genes might play a crucial role in later disease susceptibility. We
hypothesized that vitamin D pathway genes are developmentally active in the fetal lung and that these
developmental genes would be associated with asthma susceptibility and regulation in asthma.
Methods: Vitamin D pathway genes were derived from PubMed and Gene Ontology surveys. Principal component
analysis was used to identify characteristic lung development genes.
Results: Vitamin D regulated genes were markedly over-represented in normal human (odds ratio OR 2.15, 95%
confidence interval CI: 1.69-2.74) and mouse (OR 2.68, 95% CI: 2.12-3.39) developing lung transcriptomes. 38 vitamin
D pathway genes were in both developing lung transcriptomes with >63% of genes more highly expressed in the
later than earlier stages of development. In immortalized B-cells derived from 95 asthmatics and their unaffected
siblings, 12 of the 38 (31.6%) vitamin D pathway lung development genes were significantly differentially expressed
(OR 3.00, 95% CI: 1.43-6.21), whereas 11 (29%) genes were significantly differentially expressed in 43 control versus
vitamin D treated immortalized B-cells from Childhood Asthma Management Program subjects (OR 2.62, 95% CI:
1.22-5.50). 4 genes, LAMP3, PIP5K1B, SCARB2 and TXNIP were identified in both groups; each displays significant bio-
logic plausibility for a role in asthma.
Conclusions: Our findings demonstrate a significant association between early lung development and asthma–
related phenotypes for vitamin D pathway genes, supporting a genomic mechanistic basis for the epidemiologic
observations relating maternal vitamin D intake and childhood asthma susceptibility.
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The prevalence of asthma, a disease affecting 300 million
individuals worldwide [1], has risen substantially over
the past 30 years. From an epidemiologic perspective,
the increase in asthma has been greatest in industrialized
countries and in those countries undergoing rapid
urbanization [2,3]. This has led to the so-called Western
lifestyles hypothesis, which states that factors accom-
panying the transition from a predominantly rural to a
predominantly urban lifestyle may increase susceptibility
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reproduction in any medium, provided the orsuch factor is vitamin D deficiency. It has been estimated
that one billion individuals worldwide are insufficient or
deficient in vitamin D [6]. In Westernized countries,
vitamin D levels tend to be low due to both increased
urban (indoor) lifestyles and high use of sunscreen.
Multiple studies have now demonstrated an associ-
ation between lower maternal vitamin D level during
pregnancy and subsequent increased risk of childhood
wheezing or asthma. For example, in an analysis of 1,194
mother-child pairs from Boston, MA, 3-year-old chil-
dren born to mothers with vitamin D intake in the high-
est quartile during pregnancy had a 62% reduction in
risk of recurrent wheeze (adjusted odds ratio OR 0.38,
95% confidence interval CI: 0.22-0.65) [7]. Similar ana-
lyses of 1,212 and 763 mother-child pairs from Scotland. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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subsequent persistent wheeze for children with maternal
vitamin D intake in the highest quintile [8,9]. Overall,
high maternal dietary vitamin D intake during pregnancy
appears to be protective for the development of wheez-
ing outcomes (OR 0.56, 95% CI: 0.42-0.73) [10].
The fetal origins or Barker [11] hypothesis states that
in utero exposure to the maternal environment, includ-
ing diet, may influence the eventual development of
chronic disease. Globally, vitamin D has been postulated
to be important in early pregnancy, regulating key target
genes associated with implantation and implantation
tolerance [12]. Vitamin D also regulates genes involved
in the inflammation, immunity, cellular proliferation,
and apoptosis associated with obstructive airways disease
[13], likely via an epigenetic mechanism. Given the po-
tential role that vitamin D plays in pregnancy, as well as
the influence of maternal diet on subsequent childhood
respiratory outcomes, it has been postulated that vitamin
D deficiency directly affects programming within the de-
veloping fetal lung in a manner that may influence dis-
ease susceptibility [14,15]. We hypothesized that vitamin
D pathway genes are transcriptionally active and tem-
porally regulated during normal fetal lung development.
Given the association of maternal vitamin D intake to
subsequent childhood asthma, we further hypothesized
that a significant subset of vitamin D genes important to
normal fetal lung development would also be asthma
susceptibility genes. We tested this hypothesis through
an integrative analysis of developing mouse and human
fetal lung transcriptomes. We identified key vitamin D
pathway lung development genes and tested their tran-
scriptomic association with asthma susceptibility.
Methods
Derivation of the vitamin D related gene set (VDRGS)
We assembled genes associated with vitamin D using
both supervised and unsupervised approaches. In the su-
pervised approach, we used genes recorded to be associ-
ated with vitamin D structure, function, regulation and
signaling in Gene Ontology (GO, http://www.geneontol-
ogy.org/ version May 2013) [16] or Entrez Gene (http://
www.ncbi.nlm.nih.gov/gene version May 2013) databases.
In the unsupervised approach, we used 212 unique human
(195 homologous mouse) genes reported to be differen-
tially regulated post vitamin D stimulation in human lym-
phoblastoid B cell lines [17].
Microarray data
We used 3 developing lung time series datasets. The first
is an expansion of the National Center for Biotechnology
Information Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) GSE11539 [18] of C57BL6
mouse whole lung at embryonic days 9.5 (E9.5), 12.5,14.5, 16.5, 18.5, and postnatal days 0 (P0), 2, 4, 7, 11, 13,
18, 24, 30, 56 in biological duplicates profiled on Affy-
metrix Mouse Gene 1.0 ST array courtesy of Carol J.
Bult of the Jackson Laboratory, Bar Harbor, ME. The
study protocol was approved by the Jackson Laboratory
Animal Care and Use Committee #01011. The second
GSE14334 consists of 38 human fetal lung samples from
53 to 154 estimated days post conception (dpc) profiled
on the Affymetrix Human Genome U133 Plus 2.0 array
[19]. The third GSE20954 consists of developing mouse
whole lungs from E12 to P30 in duplicates profiled on
Affymetrix Mouse Genome 430 Plus 2.0 array [20].
For asthma and vitamin D transcriptomic association
analyses, we used 3 datasets: First, GSE8052 [21] consists
of Epstein–Barr virus (EBV) transformed lymphoblastoid
B-cells (LCLs) from a pediatric asthma family association
study on the Affymetrix Human Genome U133 Plus 2.0
array. We restricted the data to 95 unaffected-affected sib-
ling pairs (see Additional file 1: Table S1 and Figure S1).
Second, we used LCLs from 43 asthmatic subjects from
an ancillary genetics study of the Childhood Asthma Man-
agement Program (CAMP) [22,23] that was approved by
the Brigham and Women’s Hospital Institutional Review
Board # 1999-P-001549. All subjects or their legal guard-
ians provided written informed consent to participate in
the study protocols. LCLs were cultured in RPMI-1640
supplemented with 5% FBS and 1X Penicillin/Strepto-
mycin/L-Glutamineto an average density of 200,000 cells/
ml. The cells were then split and stimulated with sham
(control) versus 1 μM 1,25-OH vitamin D for 72 hours.
Total RNA was extracted from the cells using the
Absolutely RNA Miniprep column purification system
(Stratagene, LaJolla, CA) per manufacturer's instruc-
tions. Paired RNA samples were profiled on the Illu-
mina HumanHT-12 V4 array. Third, GSE5145 consists
of vitamin D versus sham stimulated normal human
bronchial smooth muscle cells [24].
For each developmental dataset and the first asthma
dataset, sample files were processed using the Robust
Multi-array Analysis (RMA) quantile normalization [25]
package in BioConductor (http://www.bioconductor.org/)
to produce an N × M data matrix of RMA signals in the
logarithmic base 2 (log2) scale. N is the total number of
probe sets (genes) in the microarray platform and M is
the total number of samples. The second asthma dataset
was further processed using the probe-wise non-
parametric regression function locfit in BioConductor
[26] to minimize the effects of subject or age estima-
tion–related variation in expression measurement and
to model global gene-specific developmental expression
patterns. For each probe set in a developmental dataset,
we computed the linear correlation between replicate
time series expression profiles to assess the reproduci-
bility of its sample expression profile. When a gene (its
Figure 1 Composition of the vitamin D related gene set
(VDRGS). Venn diagram of vitamin D related human gene sets
assembled using supervised (GO and Entrez Gene databases) and
unsupervised [17] approaches. Bracketed numbers (#) refer to
number of homologous mouse genes.
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lected the probe set with the maximum linear correl-
ation between replicate to be its unique representative.
In the asthma datasets, Wilcoxon signed rank test was
used to determine differential expression between the
paired samples, i.e., affected versus unaffected sibling, pre-
versus post- vitamin D per subject at p < 0.05 significance
threshold. When a gene (its Entrez Gene ID) is repre-
sented by >1 probe sets, we selected the probe set with the
smallest signed rank p value as its unique representative.
Principal component analysis for identifying characteristic
genes in a developing organ transcriptome
Each developmental dataset is a N genes × M samples data
matrix of RMA signals. First, the columns of the data
matrix were standardized to average 0 and variance 1 since
we were investigating sample variation in the sense of lin-
ear correlation, as opposed to Euclidean distance. Second,
we performed principal component analysis (PCA) of sam-
ple time points in gene space, and obtained the loading co-
efficients for each gene in principal components 1 to 3
(PC1–3) [19,27-29]. Each principal component (PC) is a
linear combination of N genes. The magnitude of the load-
ing coefficient of a gene in a given PC corresponds to its
contribution to the sample variation along that PC. For
each PC, we ranked the genes in decreasing order of its
loading coefficient magnitude. For example, the mouse
gene H2-Ab1 ranked 42 in PC2 in the developing mouse
lung dataset has the 42-nd highest loading coefficient mag-
nitude in PC2. We define the characteristic genes for a PC
to be the top 5% ranking genes in that PC. A gene that is
characteristic in any one of the PC1–3 in a given dataset is
defined to be a characteristic gene for that dataset.
Fold change, bio-ontology enrichment and overlap
analyses
The microarray reported gene expression intensity is an
RMA signal in log2 scale. Suppose that each sample in a
microarray dataset has a mutually exclusive condition
label – A or B. The log2 fold change of a gene in A rela-
tive to B is the arithmetic average in A minus the arith-
metic average in B. Fisher exact test on DAVID 6.7
http://david.abcc.ncifcrf.gov/ [30] was used to determine
specific bio-ontological enrichment in a given gene set
relative to a background gene set at p < 0.05 significance
threshold. More generally, two-sided Fisher exact test
was used to assess the significance of overlaps between
any pair of gene sets, and a 95% confidence interval (CI)
was supplied for the odds ratio (OR).
Results
The vitamin D related gene set (VDRGS)
For the supervised analysis, from GO, we found 24 GO
terms that contain character strings “vitamin D*” or“cholecalciferol*”, where * denotes a wildcard character
string. For example, the GO term “GO:0070561 vitamin
D receptor signaling pathway” contains 4 unique human
genes: CYP24A1, CYP27B1, TRIM24 and VDR. The
union of these 24 GO terms contained 67 unique human
genes. Similarly, Entrez Gene had 201 unique human
genes with a description field containing “vitamin D*” or
“cholecalciferol*”. The supervised approach from GO and
Entrez Gene combined yielded 211 unique human (215
homologous mouse) genes, see Figure 1 and Additional
file 1: Table S1. In the unsupervised approach, as noted,
we assembled 212 previously reported unique human (195
homologous mouse) genes resulting from differential ex-
pression following vitamin D stimulation [17], see Figure 1
and Additional file 1: Table S1. 10 genes were common to
the sets of genes derived using supervised and unsuper-
vised approaches: CAMP, CD274, CYP19A1, CYP24A1,
DHCR7, LGMN, MED13, NFKBIA, TNFSF4 and VDR.
Together, the supervised and unsupervised approaches
yielded 413 unique human (400 homologous mouse)
genes that we define to be the vitamin D related gene set
(VDRGS) in this study (Additional file 1: Table S1).
Derivation of developing lung characteristic gene sets
(DLCGS)
Here we identify the main contributor genes to transcrip-
tome scale sample variation in the developing whole fetal
lung using principal component analysis (PCA) following
our previous work [19,28], see Materials and Methods. We
used 2 independent developing whole lung transcriptome
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spanned the major histo-morphological stages of lung de-
velopment: pseudoglandular, canalicular, saccular and al-
veolar, GSE11539 expanded [18]. The human time series
(53 to 154 dpc) spanned the pseudoglandular and canalicu-
lar stages, GSE14334 [19].
For each time series, we applied PCA of sample time
points in transcriptome space. In each case we observed
that the sample configuration along the first three prin-
cipal components (PC1-3) correlated with age, time-to-
birth or a transition between histo-morphological stages
of lung development. The loading coefficient magnitude
of a gene in a given principal component is proportional
to its contribution to the sample variation along that
principal component, see Materials and Methods. There-
fore we define the genes with the top 5% highest loading
coefficient magnitude in any one of PC1-3 to be the de-
veloping lung characteristic gene set (DLCGS) for the
particular time series. These DLCGS consisted of 2,472
(human) and 2,495 (mouse) genes respectively. We had
previously shown that these DLCGS were enriched for
ontological attributes associated with developmental
processes in general and the developing lung structure
and function in particular [19,28] suggesting the DLCGS
qualitatively capture developing lung biology.
Over-representation of vitamin D related genes (VDRGS)
in developing lung characteristic gene sets (DLCGS)
We observed significant overlaps between the VDRGS with
both DLCGS above: 103 VDRGS genes in the C57BL6
mouse DLCGS expanded GSE11439 (OR 2.68, 95% CI:
2.12-3.39), and 92 VDRGS genes in the human DLCGS
GSE14334 (OR 2.15, 95% CI: 1.69-2.74) (Additional file 1:
Figure S1). 38 VDRGS genes were common to both mouse
and human DLCGS (Figure 2). The VDRGS was similarly
found to overlap significantly with the DLCGS of an inde-
pendent developing mouse lung time series (E12 to P30),
GSE20954 (OR 2.07, 95% CI: 1.60-2.68) [20].
Of the 38 common VDRGS-DLCGS genes, 29 (76%)
were expressed at a higher level in the later rather than
earlier stages of the developing mouse lung; whereas 24
(63%) were expressed at a higher level in the later cana-
licular than earlier pseudoglandular stages of the devel-
oping human lung (Figure 2).
Profile of 38 common VDRGS-DLCGS genes in independ-
ent pediatric asthma studies
Here we investigate the 38 VDRGS genes common to
both the C57BL6 mouse and human DLCGS in independ-
ent studies of the pediatric lymphoblastoid B-cell (LCL)
transcriptome in unaffected versus affected asthma sibling
pairs [21] and vitamin D versus control treatment of LCLs
from asthmatic subjects from the Childhood Asthma
Management Program (CAMP) [31] (Table 1).For the pediatric asthma sibling pair study [21], 2,697
genes (of 20,188 unique genes measured) were differen-
tially expressed between LCLs of 95 affected versus un-
affected siblings pairs at p < 0.05. There was a significant
overlap of 86 genes between this 2,697-gene set and the
VDRGS (OR 1.77, 95% CI: 1.38-2.27). Focusing on the
38 common VDRGS-DLCGS genes, 12 (31%) were sig-
nificantly differentially expressed between unaffected-
affected siblings: CD44, HLA-DRB1, IFIH1, IGF1*,
LAMP3, LY75, MYC, PIP5K1B*, SCARB2*, SFRP1,
TXNIP* and TYMS*, where* indicates under expression
in the affected relative to the unaffected sibling pair
(OR 3.00, 95% CI: 1.43-6.21) (Figure 3).
For the vitamin D treatment study of 43 asthmatic
CAMP subjects, 3,368 genes (of 24,960 unique genes
measured) were differentially expressed between LCLs of
vitamin D versus control treatment at p < 0.05. There
was a significant overlap of 161 genes between this
3,368-gene set and the VDRGS (OR 4.30, 95% CI: 3.50-
5.29) (Figure 3). Focusing on the 38 common VDRGS-
DLCGS genes, 11 (22%) were significantly differentially
expressed between control-vitamin D treatment: CAV1*,
CD69, IFI44*, LAMP3, NAPSA, PIP5K1B, PRNP, SAT1,
SCARB2*, TXNIP* and VASH2, where* indicates under-
expression in vitamin D relative to control treatment
(OR 2.62, 95% CI: 1.22-5.50) (Table 1). Four VDRGS-
DLCGS genes were common to both asthma/VDRGS-
DLCGS analyses above: LAMP3, PIP5K1B2, SCARB2 and
TXNIP. Interestingly, the SNP rs975645 of PIP5K1B2 was
found to be associated with asthma under a dominant gen-
etic model in our previous CAMP study (p = 0.004) [32].
In an unrelated study of vitamin D stimulated normal
human bronchial smooth muscle cells GSE5145 [24], of
the 405 genes that were 2-fold differentially expressed
between vitamin D versus control treatment, we found a
significant overlap of 9 genes with the VDRGS (OR 5.09,
95% CI: 2.38-10.51) (Figure 3). Of these 9 genes, INSIG1
was also in VDRGS-DLCGS.
Discussion
We have performed a multi-staged analysis that demon-
strates the prominence of vitamin D within the develop-
ing lung transcriptome and that supports the role of
these developmental genes in asthma pathogenesis. Spe-
cifically, through interrogation of both supervised (litera-
ture based) and unsupervised (ChIP-Seq based) lists of
vitamin D pathway genes, we have demonstrated that a
significant proportion of vitamin D response elements
are transcriptomically active during both normal human
and mouse lung development. These vitamin D genes
generally increase in expression throughout fetal lung
development, with peak expression just prior to birth.
We subsequently have shown that approximately 1/3 (12
of 38) of the vitamin D genes that jointly influence both
Figure 2 Over-representation of vitamin D related genes in the developing lung transcriptome. A: Contingency tables of overlaps
between VDRGS and 3 independent developing lung characteristic gene sets (DLCGS). B: Heat maps of 38 VDRGS-DLCGS genes in the C57BL6
mouse (left) and human (right) developing lung time series. The expression signal of each gene in each time series has been standardized to
average 0, variance 1 across their respective time intervals. Four sentinel genes – BUB1, TOP2A, SFTPB and SFTPC – included for visual reference.
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tially expressed in LCLs derived from asthmatic children
as compared to non-asthmatic sibling controls. Overall,
vitamin D lung developmental genes were three times as
likely to be differentially expressed in these asthmatics,
when compared to non-vitamin D genes. Finally, we
noted that, of the 12 vitamin D lung developmentalgenes transcriptomically related to asthma susceptibility,
4 – LAMP1, PIP5K1B, SCARB2, and TXNIP – were
significantly differentially expressed upon administra-
tion of vitamin D to cells derived from asthmatic
children. Thus, multiple common vitamin D response
elements appear to be important in both the developing
lung and asthma, thereby providing a genomic rationale
Table 1 38 Vitamin D regulated lung developmental genes and their log2 fold changes in 3 asthma and vitamin D
stimulation studies: Lymphoblastoid B-cells of pediatric asthma (GSE8052) and vitamin D treatment (CAMP 43), and
normal human bronchial smooth muscle vitamin D treatment (GSE5145)
Gene ID Gene Supervised Unsupervised GSE8052 asthma/unaffected CAMP 43 vitamin D/control GSE5145 vitamin D/control
174 AFP S - 0.007 −0.047 0.094
213 ALB S - −0.023 0.074 −0.130
332 BIRC5 S - −0.133 −0.030 0.055
355 FAS S - 0.098 0.060 0.189
857 CAV1 S - −0.058 −0.169 0.141
950 SCARB2 - U −0.341 −0.124 −0.174
960 CD44 S - 0.155 0.107 0.325
969 CD69 - U 0.046 0.239 0.022
1080 CFTR S - 0.022 −0.103 0.184
1520 CTSS - U 0.053 0.026 0.301
1636 ACE S - 0.062 −0.148 −0.262
2028 ENPEP S - 0.025 0.047 0.651
2222 FDFT1 - U 0.080 0.056 0.125
3123 HLA-DRB1 S - 0.130 −0.090 −0.107
3248 HPGD S - 0.022 −0.040 −0.134
3479 IGF1 S - −0.094 0.071 0.436
3575 IL7R S - 0.027 0.075 0.310
3638 INSIG1 - U −0.025 0.065 1.223
4065 LY75 - U 0.208 0.108 −0.163
4609 MYC S - 0.124 0.124 −0.239
5251 PHEX S - 0.005 0.031 −0.084
5621 PRNP - U 0.036 0.101 0.362
0.362 PTGS2 S - 0.013 0.087 0.044
6303 SAT1 - U 0.077 0.141 0.064
6307 SC4MOL - U 0.070 0.058 0.297
6422 SFRP1 S - 0.084 0.054 −0.335
6696 SPP1 S - −0.002 −0.073 −0.035
6781 STC1 S - −0.052 −0.085 −0.401
7298 TYMS S - −0.062 0.032 −0.115
8395 PIP5K1B - U −0.239 0.149 0.107
9476 NAPSA - U −0.032 0.388 0.036
10561 IFI44 - U −0.183 −0.098 −0.326
10628 TXNIP S - −0.211 −0.360 −0.151
27074 LAMP3 - U 0.127 0.080 0.097
54541 DDIT4 - U 0.080 −0.018 0.456
64135 IFIH1 - U 0.178 0.058 −0.243
79161 TMEM243 - U 0.000 0.054 0.168
79805 VASH2 - U 0.090 0.302 0.179
Bold log2 values indicate statistical significance.
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asthma susceptibility.
This work lends credence to the evolving literature
surrounding the developmental origins hypothesis ofcomplex disease pathogenesis. Prior work have estab-
lished that dietary changes, including protein and caloric
restriction, as well as environmental exposures in preg-
nant animals can result in changes in gene expression in
Figure 3 Over-representation of vitamin D genes in 3 asthma and vitamin D stimulation studies. Contingency tables of overlaps between
VDRGS (and 38 VDRGS-DLCGS) and significantly differentially expressed genes in lymphoblastoid B-cells of pediatric asthma (GSE8052) and vitamin
D treatment (CAMP 43), and normal human bronchial smooth muscle vitamin D treatment (GSE5145) studies.
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over, in humans, maternal vitamin D levels affect both
placental calcium transport and bone mass in later life.
These effects are thought to be mediated by vitamin D
induction of the PMCA (plasma membrane Ca2+ ATPase)
gene [8,37]. While the current study was not designed to
demonstrate a direct correlation between maternal vita-
min D status and neonatal outcomes, it does clearly indi-
cate that vitamin D regulated processes are a part of the
normal fetal lung developmental process. Combining this
with the strong epidemiologic evidence linking maternal
vitamin D status during pregnancy to subsequent asthma,
our data suggest that maternal vitamin D insufficiency
may lead to differential developmental regulation of key
vitamin D genes within the fetal lung and thus, increase
risk of childhood asthma. This hypothesis is further sup-
ported by the differences in expression of a significant
number of developmental vitamin D genes in siblings dis-
cordant for asthma.
Our data further suggest that a subset of the lung de-
velopmental vitamin D asthma genes continue to be ac-
tively regulated in later life by vitamin D, and thus, may
continue to modify the asthma phenotype. The 4 genes
that demonstrate this phenomenon in immortalized B
cells derived directly from persistent childhood asthmatics
likely represent a subset of vitamin D pathway genes in-
volved in the immune mediation of asthma. Given their
fetal lung and subsequent immune cell localization, it is
possible that the remainder of the developmental 12 vita-
min D genes that are differentially expressed in asthma
may influence asthma in cells specific to the lung, such as
epithelial or airway smooth muscle cells.
As mentioned, 4 of the developmental genes: LAMP1,
PIP5K1B, SCARB2 and TXNIP, were differentially
expressed in both asthma and upon stimulation ofimmortalized B-cells derived from asthmatics, suggest-
ing a possible role of these genes in modulating the im-
mune response in asthma. Interestingly, although these
genes have generally not been implicated in allergic air-
ways disease, each of these genes may be related to
asthma pathogenesis via a distinct molecular mechan-
ism. TXNIP, also known as vitamin D3 up-regulated
protein 1, is required for the development of natural
killer cells [38]. In turn, CD4 + Vα24+ natural killer
cells are significantly decreased in association with
infection-associated asthma exacerbations and sputum
eosinophil counts [39]. Notably, our microarray associ-
ation demonstrated decreased expression of TXNIP in
asthma; this association has been independently vali-
dated in a comparison of active asthmatics vs. normal
volunteers [40].
While the other three genes have not been associated
with asthma, they provide potentially interesting insights
into the diversity of vitamin D biology. LAMP3 appears
to be a marker of dendritic cell maturation [41] and has
been implicated in the pathogenesis of psoriasis vulgaris
[42]. PIP5K1B regulates calcium signaling in mast cells
[43]. Both the dendritic cell and the mast cell are key
regulators in the initiation of the asthmatic inflammatory
response. Furthermore, the SNP rs975645 of PIP5K1B2
was found to be associated with asthma under a domin-
ant genetic model in our previous CAMP study (p =
0.004) [32]. In lieu of direct actions on inflammatory
cells, SCAR2B appears to modulate the normal matur-
ation of phagosomes and autophagosomes [44,45]. While
the exact role of autophagy in asthma remains to be de-
termined, it has been hypothesized that autophagy is
likely an important modulator of the lack of viral-induced
apoptosis noted in subjects with asthma [46]. Consistent
with this, a recent brief report noted the presence of
Kho et al. BMC Medical Genomics 2013, 6:47 Page 8 of 9
http://www.biomedcentral.com/1755-8794/6/47autophagosomes in the airways of a subject with asthma; a
comparable tissue from a control subject failed to detect
any autophagosomes [47].
There are several limitations to our data. Our human
lung samples were obtained from healthy aborted fetuses
and thus inherently limited in their gestational age range
to ≤20 estimated weeks. While the vitamin D pathway
appears to be active in early fetal development [12], it is
unclear if perturbations in early or late gestation are
most salient to asthma susceptibility. For this reason, we
intersected our human developmental vitamin D list with
a murine developmental dataset in which later develop-
mental time periods were represented. Our sampling tech-
nique also precludes us from specifically ascertaining the
direct effect of maternal vitamin D levels on the develop-
ing human lung. Instead, we focused on a combined ap-
proach that focused on the identification of significant
vitamin D regulatory genes from the literature and a care-
fully performed ChIP-Seq study of the vitamin D receptor
[17]. Finally, our asthma expression dataset analyses were
performed in immortalized B-cells derived from asth-
matics. While this may not specifically generalize the find-
ings of the fetal lung expression datasets, the B-cell is a
relevant asthma target cell [48-50] supporting the validity
of these analyses. Only a small number of genes are specif-
ically affected by the immortalization process [51]; none
of these were among our reported vitamin D genes. More-
over, we have been able to previously correlate expression
response of these genes to clinical asthma outcomes [31],
further supporting the validity of our approach.
Conclusions
In conclusion, we have demonstrated that vitamin D
genes are actively regulated in the developing human
fetal lung and that a disproportionate number of these
genes are differentially regulated in asthma. Not only
does our study provide a mechanistic basis that helps to
explain the developmental associations of vitamin D
with asthma, it may also provide a methodologic blue-
print for rationally interrogating diverse developmental
pathways for their genomic association with subsequent
disease outcomes.
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